Rivaroxaban (Xarelto, BAY59-7939)

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Non-valvular Atrial Fibrillation (NVAF)

Conditions

Non-valvular Atrial Fibrillation (NVAF)

Trial Timeline

May 13, 2020 → Jan 16, 2023

NCT ID

NCT04356989

About Rivaroxaban (Xarelto, BAY59-7939)

Rivaroxaban (Xarelto, BAY59-7939) is a pre-clinical stage product being developed by Bayer for Non-valvular Atrial Fibrillation (NVAF). The current trial status is completed. This product is registered under clinical trial identifier NCT04356989. Target conditions include Non-valvular Atrial Fibrillation (NVAF).

What happened to similar drugs?

2 of 3 similar drugs in Non-valvular Atrial Fibrillation (NVAF) were approved

Approved (2) Terminated (0) Active (1)

✅Edoxaban + Aspirin and Clopidogrel + Aspirin and WarfarinDaiichi SankyoApproved

✅ApixabanBristol Myers SquibbApproved

🔄DU-176b 15mg + DU-176b 30mg + DU-176b 60mgDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06193863	Pre-clinical	Active	Jun 18, 2024	Dec 31, 2026	Prevention of Venous Thromboembolism
NCT04923139	Pre-clinical	Completed	Jan 24, 2022	Dec 31, 2022	Treatment of Venous Thromboembolism
NCT04356989	Pre-clinical	Completed	May 13, 2020	Jan 16, 2023	Non-valvular Atrial Fibrillation (NVAF)
NCT04174859	Pre-clinical	Completed	Dec 10, 2019	Dec 12, 2022	Non-valvular Atrial Fibrillation
NCT03455439	Pre-clinical	Completed	Mar 16, 2018	Jan 11, 2022	Heart Failure
NCT03284762	Pre-clinical	Completed	Sep 11, 2017	Nov 20, 2019	Atrial Fibrillation
NCT03214172	Pre-clinical	Completed	Jul 15, 2017	Sep 15, 2017	Venous Thromboembolism
NCT02975453	Pre-clinical	Completed	Dec 5, 2016	Aug 26, 2020	Atrial Fibrillation
NCT03242278	Pre-clinical	Completed	Feb 12, 2016	Mar 1, 2016	Atrial Fibrillation
NCT02564718	Phase 1/2	Completed	Nov 19, 2015	Dec 18, 2017	Thromboembolism
NCT02558465	Pre-clinical	Completed	Nov 13, 2015	May 31, 2021	Venous Thromboembolism
NCT02309411	Phase 2	Completed	Jan 15, 2015	Apr 5, 2017	Venous Thromboembolism
NCT02262676	Pre-clinical	Completed	Oct 1, 2014	May 1, 2015	Atrial Fibrillation
NCT01523418	Pre-clinical	Withdrawn	Oct 1, 2014	Nov 1, 2016	Prophylaxis, Thromboembolism, Venous
NCT01839357	Phase 3	Completed	Aug 1, 2013	Dec 1, 2014	Atrial Fibrillation
NCT01855100	Pre-clinical	Completed	Jul 1, 2013	Dec 1, 2014	Venous Thrombosis
NCT01855139	Pre-clinical	Completed	Jul 1, 2013	Dec 1, 2014	Atrial Fibrillation
NCT01853800	Phase 1	Completed	May 1, 2013	Aug 1, 2013	Biological Availability
NCT01805544	Pre-clinical	Completed	May 1, 2013	Jun 1, 2015	Venous Thrombosis
NCT01805531	Pre-clinical	Completed	Apr 1, 2013	Mar 1, 2015	Atrial Fibrillation

Competing Products

17 competing products in Non-valvular Atrial Fibrillation (NVAF)

See all competitors

Product	Company	Stage	Hype Score
Edoxaban	Daiichi Sankyo	Pre-clinical	26
DU-176b 15mg + DU-176b 30mg + DU-176b 60mg	Daiichi Sankyo	Phase 3	40
Edoxaban + Aspirin and Clopidogrel + Aspirin and Warfarin	Daiichi Sankyo	Approved	39
Edoxaban	Daiichi Sankyo	Pre-clinical	26
AZD0837 + Aspirin	AstraZeneca	Phase 2	35
Apixaban + Warfarin	Pfizer	Pre-clinical	26
Warfarin + Apixaban	Pfizer	Pre-clinical	26
Apixaban	Bristol Myers Squibb	Approved	43
Apixaban	Bristol Myers Squibb	Pre-clinical	18
Rivaroxaban(Xarelto,BAY 59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto,Bay 59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY59-7939) + Warfarin	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY-597939) + VKAs	Bayer	Pre-clinical	23
Non-VKA Oral Anticoagulants (NOAC)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto_ BAY59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY59-7939) + Apixaban (Eliquis) + Dabigatran etexilate (Pradaxa) + Warfarin (Marevan)	Bayer	Pre-clinical	15